Currentblue cross blue shield - louisianaPolicy 00662

Hydrogel Spacer use During Radiotherapy for Prostate Cancer

Defines coverage and medical necessity criteria for implanted hydrogel spacers placed between the prostate and rectum for patients undergoing definitive external beam radiotherapy for prostate cancer, and states noncoverage for other indications and specific radiation modalities.

Policy Summary

Payerblue cross blue shield - louisiana

PolicyHydrogel Spacer use During Radiotherapy for Prostate Cancer

Policy CodePolicy 00662

Change TypeCoverage criteria revised (eligible modalities broadened then limited to photon-based); exclusions added

Effective Date04/04/2026

Next Review Date01/2027

Key ActionProviders must document that benefits are available in the member's contract and that placement is associated with primary definitive photon-based external beam radiotherapy (3D conformal, IMRT, or SBRT) for prostate cancer.

SourceLink

POLICY UPDATE CHANGES

01/02/2025: Removed 'low risk or intermediate risk' restriction and added 'any form of external beam radiation therapy (3D conformal, IMRT, SBRT)' to be eligible for coverage; removed patient selection criteria and policy guideline sections.

01/07/2026: Added 'only Photon - based' to the eligible for coverage statement and added that hydrogel spacer use for prostate brachytherapy or proton beam therapy (PBT) is not medically necessary.

1Covered Major Indication (photon EBRT)

2Not Covered Modalities (brachytherapy, PBT)

55874

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Summary

This policy defines coverage and medical necessity criteria for implanted hydrogel spacers placed between the prostate and rectum for patients undergoing definitive external beam radiotherapy for prostate cancer. The scope includes eligibility for placement when benefits are available in the member's contract and when medical necessity criteria and guidelines are met. The policy status is CURRENT and applies to products administered or underwritten by Blue Cross and Blue Shield of Louisiana.

Policy title: "Hydrogel Spacer use During Radiotherapy for Prostate Cancer" (Policy # 00662). Current Effective Date: 04/04/2026. Last review: 01/07/2026. Next scheduled review: 01/01/2027.

Key Facts

Covered Major IndicationPhoton-based external beam radiation therapy (3D conformal, IMRT, SBRT)

Not Covered ModalitiesProstate brachytherapy and proton beam therapy (PBT)

Key CPT Code Referenced55874

Medical-Necessity Criteria

Eligible for Coverage / Medically Necessary

Covered when ALL of the following are met:

ALL of the following

ALL of the following
- Benefits are available in the member's contract/certificate
- Medical necessity criteria and guidelines are met
- Implant indication
  - Radiation modalities eligible
    3D conformal external beam radiation therapy (photon-based)

Provider Actions & Billing Impact

Documentation Required

Eligibility documentation

Document that benefits are available in the member's contract/certificate and that hydrogel spacer placement is associated with primary definitive photon-based external beam radiotherapy (3D conformal, IMRT, or SBRT) for prostate cancer.

55874

Denial Risk

Denial for excluded modalities/indications

Claims for hydrogel spacer placement for prostate brachytherapy, proton beam therapy (PBT), or for indications other than primary definitive photon-based external beam radiotherapy for prostate cancer risk denial as not medically necessary.

55874

Coding

Associated CPT codesCPT

55874

Placement of biodegradable rectal spacer (per typical CPT descriptor - local policy lists this code)

HCPCS codesHCPCS

No codes listed

ICD-10 DiagnosisICD-10

All related diagnoses

Policy applies to all related prostate cancer diagnoses

Background & Evidence

Hydrogel spacers are biodegradable implants (e.g., SpaceOAR, Barrigel, BioProtect Balloon Implant) intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy to reduce rectal radiation dose and associated toxicity. They typically remain in place for approximately 3 months before being absorbed.

Randomized controlled trials and systematic reviews demonstrate reductions in late rectal toxicity with spacer use (for example, Mariados et al. showed reduced late [3–15 month] rectal toxicity and Hamstra et al. reported 0% grade ≥2 rectal toxicity with spacer vs 5.7% without at 36 months). Systematic reviews and meta-analyses have associated perirectal spacer use with lower likelihood of early and late grade ≥2 rectal toxicity, though not consistently with differences in grade ≥3 GI events or bowel-related quality-of-life in some analyses. Despite these trial data, real-world safety signals, including a MAUDE database review identifying reported serious adverse events (approximately 85 events with ~70% graded 3–5, including some grade 4 events and one death), have prompted caution and recommendations for careful consideration, governance, and audit when using spacers.

Study / Source	Key finding
Phase 3 RCT (Mariados et al.)	Significant reduction in late (3-15 month) rectal toxicity with spacer; initial 6-month results showed no significant reduction in rectal adverse events
Hamstra et al. 36-month results	0% grade ≥2 rectal toxicity with spacer vs 5.7% without (P=.012); reduction in some urinary and sexual outcomes noted
Systematic reviews (Armstrong; Wong et al.)	Perirectal spacer associated with lower likelihood of early and late grade ≥2 rectal toxicity; no difference in grade ≥3 GI events or bowel-related QoL in some analyses
MAUDE safety signals	Review identified 85 reported adverse events with ~70% graded 3-5 including grade 4 events and one death; prompted caution over real-world serious events

Medicare Determinations

Determination	Effective	Type/Number	Notes
No national coverage determination; local Medicare carriers discretion	No national NCD date specified	NCD	In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers

Revision History

01/02/2025material change

Removed 'low risk or intermediate risk' restriction and removed prior patient selection criteria; broadened eligible radiation techniques to include any form of external beam radiation therapy (3D conformal, IMRT, SBRT).

01/07/2026material changeLatest

Narrowed eligible radiation modalities by specifying 'only Photon - based' external beam radiation therapy; added that hydrogel spacer use for prostate brachytherapy or proton beam therapy (PBT) is considered not medically necessary.